| Bioactivity | TrkA-IN-4, a potent, orally active and allosteric TrkA inhibitor, is a prodrug of TrkA-IN-3 (HY-151948). TrkA-IN-4 exhibits potent antinociceptive effects[1]. |
| Invitro | TrkA-IN-4 (化合物 39) 在浓度为 1 μM 和 0.1 μM 时对 TrkA 的抑制率分别为 65.1% 和 46.3%[1]。 |
| In Vivo | TrkA-IN-4 (化合物 39) (0.9375-120 mg/kg; i.g.) 在雄性小鼠的热板测试中，给药后3小时表现出最大抗伤害感受效应，ED50 值为 7.836 mg/kg[1]。 Animal Model: |
| Name | TrkA-IN-4 |
| Formula | C27H21F3N4O5 |
| Molar Mass | 538.47 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Tang S, et, al. Design, development and evaluation of a prodrug-type TrkA-selective inhibitor with antinociceptive effects in vivo. Eur J Med Chem. 2023 Jan 5;245(Pt 2):114901. |